Back to Awarded Treatment Trials


Awarded Trial: 02-STN-007

Grant ID

02-STN-007

Illness

Schizophrenia

Primary Drug/Intervention

Celecoxib

Primary Dosage

400 mg

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Müller

Sample Size

50

Duration of Study Period for Each Subject

5 weeks

Outcome Measurements

PANSS, EPS scale

Results

In a trial with 50 patients, adjunctive treatment with this anti-inflammatory drug produced modest symptoms improvements. Two additional trials in schizophrenia and one in bipolar disorder are underway to further evaluate this treatment.

Publication

Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Möller HJ, Schwarz MJ. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002 Jun;159(6):1029-34.

Link

http://www.ncbi.nlm.nih.gov/pubmed/12042193

PI Name

Norbert Müller

Degree

MD

Center

Department of Psychiatry

Institution

Ludwig-Maximilians Universitaet

Address

Nussbaumstr. 7

City or Town

Munich

State or Province

N/A

Zip or Postal Code

80336

Country

Germany

Email Address

norbert.mueller@med.uni-muenchen.de